The venture arm of European chemical company invests in companies developing technologies that are of strategic interest. The fund is flexible regarding investment and partnerships; most investments are made in Series A rounds but both seed-stage opportunities and later-stage opportunities may be of interest. Initial investments typically range from $1-7 million, and the fund generally syndicates with other investors. The fund will consider opportunities globally. In addition to capital the fund is able to provide strategic guidance and technical expertise to its portfolio companies.

Within the life science sector, the fund is interested in excipients, custom manufacturing and formulation, medical device coatings, agrochemicals, plant biotech (particularly technology that increases crop yield such as GMOs), industrial biotech (including fermentation), and medical uses of nanotechnology (including nanotech mechanisms for drug delivery). Within the coatings subsector, the fund is particularly interested in coatings that can be applied to polymers/surface technologies developed by the funds parent company.

The fund generally invests in pre-revenue companies that have developed proof of concept data or a prototype, and which have filed for patents. The fund always request a board seat subsequent to investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that was founded in 2011 and is based in China is managing one fund with committed capital of $140million. The firm typically makes equity investment into life science companies at various stages. The investment size generally ranges from $10 million to $15 million over the life of an investment. The firm seeks to make 3-5 allocations in the next year. The firm focuses on companies that are based in the China and the US.

The firm is currently looking for new investment opportunities in Biotechnology R&D, Therapeutics & Diagnostics, Pharmaceuticals, Medical Devices and Healthcare IT spaces. The firm is very opportunistic in terms of subsectors and indications. The firm is interested in in-license products or technologies for development from companies outside of China, such as US-based companies. The firm also seeks to invest in orphan drugs. Prior investments have included medical device companies, diagnostics companies, CRO and distributors. The firm will consider companies in all stages, depending on the opportunity.

The firm seeks to invest in both private and public companies. The firm has no specific requirements for companies’ management team, revenue or EBITDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture investment and development firm based in the Southern United Sates provides investment and incubation services to start-up and early-stage medical device companies. The firm provides seed capital (equity) ranging from $500K to $2M with follow-on capital of up to $5M. The firm also considers investment opportunities with smaller than typically accepted venture capital market size thresholds. The firm is geographically agnostic and is actively seeking new opportunities. 

The firm is currently looking for medical device companies/start-ups developing products with a 510(k) regulatory pathway. The firm primarily focuses on Class II medical devices but will also consider Class III. Preferably, the product should have a prototype and animal data. The firm is open to all target markets, but is more interested in cardiovascular, interventional cardiology, interventional radiology, cardiac surgery, vascular surgery, critical care, consumable product, patient care, and orthopedic markets.

The firm takes an active role in the management of portfolio companies. The firm seeks Board representation and participation as Executive Management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm funded by a single LP based in the Western United States invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

The firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. Generally, the firm focuses on opportunities that avoid or mitigate FDA regulatory risks. The firm is agnostic in terms of subsectors and indications, but does not consider orphan indications. The firm will only consider technologies with proof of concept. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm prefers to take a board seat but is generally flexible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An angel group is made up healthcare professionals is seeking to invest in technologies that significantly advance the standard of care. The group considers companies at a range of stages and is geographically agnostic. Since the members are investing their own capital, the investment size and capital structure are highly flexible. The group is actively seeking new investment opportunities, and is open to leading financing rounds.

The group is interested in therapeutics, diagnostics, and medical devices. While the group will consider most any indication and technology type, the group currently has a particular interest in cell therapy and in the oncology sector. In general, the group is not interested in dermatology. The group will only consider products that have shown human clinical efficacy; in the case of therapeutics, the group generally looks at phase II companies but if a company has obtained human efficacy data in phase I, the group would consider the opportunity. 

The group invests in both private and public companies. The group performs deep scientific due diligence on all the opportunities that the group takes part in, often conducted by the group’s members.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate investment arm of a Japanese biotechnology company primarily makes early stage investments solely in the Life Sciences. The firm recently raised a new fund in March 2014 and looks to make about 2-3 new investments in the next 12 months. The firm typically allocates USD 1-2 million per round and up to USD 3 million per company. The firm can invest globally, with particular interests in the USA and Europe. The firm is actively seeking new investment opportunities.

The firm seeks to invest in therapeutics, in-vitro diagnostic devices, medical devices and drug discovery platforms. For therapeutics, the firm looks for small molecules, biologics, as well as biosimilars and reformulated drugs. The firm is opportunistic in terms of indications and is particularly interested in orphan indications. The firm will consider products in all stages of development. However, the firm typically invests in products that are in pre-clinical and early-clinical. For medical devices, the firm is also opportunistic in terms of indications; however the firm is only interested in devices with a therapeutic focus.   

The firm will only co-invest with other investors in opportunities outside of Japan. For that reason, the firm prefers opportunities with a syndicate in place. The firm typically requests board observation rights in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a United Kingdom based media and information firm is looking to make allocations into Healthcare IT. The firm focuses on information technology and media companies based in the US, Europe, and Israel. The firm can allocate up to US$10M per company, preferably in the range of $3-5M. The firm will invest at any stage of a company’s development, from early/seed stage to growth capital. The firm is actively seeking new investment opportunities.

The firm seeks to invest across the Healthcare IT sector. The firm looks for any type of company that provides data and software to healthcare and life science companies including genomics and proteomics. Historically in the life sciences, the firm invested in a bioinformatics company that provides informatics to improve speed and productivity of drug delivery.

The firm may take a board or an observer seat depending on the amount of investment. For commercial stage companies, the firm looks for companies to have a revenue run rate of $1M plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com